U.S. authorities now allege that the two top officials of CANARX, a Windsor, Ontario company, ran a long-running scheme to illegally import prescription drugs into the country. According to court records filed Tuesday, John Thomas Howard, the company's treasurer and a director, was arrested Sunday on smuggling and conspiracy charges. His brother, Bob Howard, the president and a director, is also wanted, and has not yet been taken into custody. No plea has been filed. These are allegations, and the Howards deny all the charges. Still, the affidavit from FDA special agent Dustin Dobbs states there is probable cause to believe the company illegally imported or caused the illegal importation of prescription drugs into the United States.
The case matters beyond two men because of the model they represented. CANARX was one of the alternative funding programs, or AFPs, that a CNBC investigation said are spreading through private and public employers by offering high-cost specialty drugs at lower prices. The company described itself as the safest such program in the industry and said it sourced medicines from Canada, the United Kingdom, Australia and New Zealand. The FDA has said that in most circumstances a person cannot import prescription drugs from other countries as substitutes for FDA-approved drugs. Affidavit language aside, the affidavit does not say which medications were involved, and that gap should be closed quickly in court.
The company's record is not new. The FDA seized medication shipped by CANARX in 2023 that it said was potentially misbranded and counterfeit, and its 2019 warning letter objected to substituting unapproved drugs for FDA-approved ones. Morris, the general counsel, responded then by agreeing to stop importing drugs that must be administered by a doctor. That concession suggests the company knew where the line was. Gilead Sciences' pending civil lawsuit, which accuses CANARX and others of illegally importing its HIV medication Biktarvy, adds a second front.
Patients are the people most exposed when this supply chain fails. The affidavit cites safety risks, and the CNBC reporting found drugs moving through channels the manufacturers never authorized. Employers that require staff to use an AFP should ask hard questions about where those drugs come from before the next contract renewal. Regulators should publish which products were involved and clarify the import rules that AFPs have leaned on. Congress should decide whether personal-use exceptions were ever meant to support a business model built on shipping specialty drugs from abroad. The Howards are entitled to defend themselves in court, and they should. But the law is not vague about the central question, and the government has a duty to test these claims quickly and openly.